Mitolactol: Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5284380 |
| CHEMBL ID | 2104612 |
| CHEBI ID | 135311 |
| SCHEMBL ID | 8455 |
| MeSH ID | M0013947 |
| Synonym |
|---|
| 1,6-dibromo-1,6-dideoxy-d-galactitol |
| elobromol |
| 10318-26-0 |
| mitolactol |
| dibromdulcitol |
| dibromodulcitol |
| 1,6-dibromodideoxydulcitol |
| nci-c04795 |
| dibromdulcit |
| nsc-104800 |
| DBD , |
| 1,6-dibromodulcitol |
| nsc 104800 |
| (2r,3s,4r,5s)-1,6-dibromohexane-2,3,4,5-tetrol |
| mitolactol [inn] |
| galactitol, 1,6-dibromo-1,6-dideoxy- |
| 1,6-dibromo-1,6-dideoxydulcitol (van) |
| 1,6-dibromo-1,6-dideoxydulcitol |
| dbd (alcohol) |
| ai3-52708 |
| mitolactolum [inn-latin] |
| ccris 6226 |
| CHEBI:135311 |
| unii-lj2p1sik8y |
| lj2p1sik8y , |
| mitolactolum |
| CHEMBL2104612 |
| mitolactol [who-dd] |
| mitolactol [mart.] |
| mitolactol [mi] |
| SCHEMBL8455 |
| DTXSID8020414 |
| VFKZTMPDYBFSTM-GUCUJZIJSA-N |
| 1,6-dibromo-1,6-dideoxy-d-galactitol;1,6-dibromo-1,6-dideoxy-d-galactitol |
| DB12916 |
| Q27283015 |
| AKOS040747169 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The mannitol derivatives were selectively myelosuppressive, being twice as toxic towards granulocytes as towards lymphocytes." | ( Toxicity, antitumour and haematological effects of 1,2-anhydro-6-bromogalactitol and d-mannitol: a comparison with the related dibromo- and dianhydro-derivatives. Hegedüs, L; Horváth, IP; Jarman, M; Somfai-Relle, S, 1982) | 0.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In parallel to the clinical study CMEA 0102 and an experimental study with animal models the effectivity of carminomycin (CRM) in combination with dibromodulcitol (DBD) was tested on human mesothelioma cells in vitro." | ( [The effectivity of carminomycin in combination with dibromodulcitol on human tumor cells in vitro (author's transl)]. Nissen, E; Projan, A; Tanneberger, S, 1981) | 0.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Approximate values were estimated for the oral bioavailability of DBD." | ( Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD. Csetényi, J; Eckhardt, S; Hegedüs, I; Hindy, I; Horváth, IP; Institoris, I; Kerpel-Fronius, S, 1982) | 0.26 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The limited therapeutic benefit did not justify the toxicity produced, and suggested that intensive dosage schedules of vincristine, and use of low dose hexamethylmelamine during the time of anticipated hematologic nadir counts would not be of substantial benefit." | ( Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: an ECOG pilot study. Taylor, SG; Wolter, J, 1981) | 0.26 |
| " The long retention of the firmly bound hexitol moieties in the body may be an indicator of the cumulative potency of DBD and must be taken into consideration by developing dosage schedules." | ( Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD. Csetényi, J; Eckhardt, S; Hegedüs, I; Hindy, I; Horváth, IP; Institoris, I; Kerpel-Fronius, S, 1982) | 0.26 |
| " The shape of the DAG dose-response curves was similar to that of those observed for most oncolytic agents." | ( Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol. Levin, VA; Wheeler, KT, 1982) | 0.26 |
| Class | Description |
|---|---|
| alcohol | A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. |
| organobromine compound | A compound containing at least one carbon-bromine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 124 (71.68) | 18.7374 |
| 1990's | 31 (17.92) | 18.2507 |
| 2000's | 13 (7.51) | 29.6817 |
| 2010's | 5 (2.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.68) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 48 (25.95%) | 5.53% |
| Reviews | 12 (6.49%) | 6.00% |
| Case Studies | 7 (3.78%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 118 (63.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY [NCT00002620] | Phase 3 | 212 participants (Anticipated) | Interventional | 1994-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 1.97 | 1 | 0 | 4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid | antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite |
| adenine [no description available] | 1.96 | 1 | 0 | 6-aminopurines; purine nucleobase | Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| porphobilinogen [no description available] | 1.97 | 1 | 0 | aralkylamino compound; dicarboxylic acid; pyrroles | Escherichia coli metabolite; metabolite; mouse metabolite |
| putrescine [no description available] | 1.95 | 1 | 0 | alkane-alpha,omega-diamine | antioxidant; fundamental metabolite |
| spermidine [no description available] | 1.95 | 1 | 0 | polyazaalkane; triamine | autophagy inducer; fundamental metabolite; geroprotector |
| altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. | 5.64 | 7 | 3 | triamino-1,3,5-triazine | |
| amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity. | 1.96 | 1 | 0 | acridines; aromatic ether; sulfonamide | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
| busulfan [no description available] | 2.35 | 2 | 0 | methanesulfonate ester | alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent |
| verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. | 1.98 | 1 | 0 | aromatic ether; nitrile; polyether; tertiary amino compound | |
| carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. | 9.28 | 12 | 6 | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent |
| chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. | 3.45 | 2 | 0 | aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent |
| eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2. | 4.02 | 2 | 0 | alpha-amino acid; fluoroamino acid | trypanocidal drug |
| fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth. | 7.77 | 16 | 4 | nucleobase analogue; organofluorine compound | antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic |
| hexamethylene bisacetamide N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208 | 3.06 | 1 | 0 | acetamides | |
| hydroxyurea [no description available] | 6.39 | 7 | 2 | one-carbon compound; ureas | antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent |
| ifosfamide [no description available] | 9.29 | 1 | 1 | ifosfamides | alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic |
| lomustine [no description available] | 7.46 | 9 | 5 | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent |
| mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR. | 3.46 | 2 | 0 | nitrogen mustard; organochlorine compound | alkylating agent |
| mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. | 3.47 | 2 | 0 | dihydroxyanthraquinone | analgesic; antineoplastic agent |
| phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups. | 1.96 | 1 | 0 | barbiturates | anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative |
| procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. | 8.44 | 16 | 8 | benzamides; hydrazines | antineoplastic agent |
| pyrimethamine Maloprim: contains above 2 cpds | 1.95 | 1 | 0 | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| semustine Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.. semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group. | 7.65 | 3 | 0 | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent; carcinogenic agent |
| streptonigrin [no description available] | 3.04 | 1 | 0 | pyridines; quinolone | antimicrobial agent; antineoplastic agent |
| tegafur [no description available] | 3.34 | 1 | 1 | organohalogen compound; pyrimidines | |
| temozolomide [no description available] | 3.23 | 1 | 0 | imidazotetrazine; monocarboxylic acid amide; triazene derivative | alkylating agent; antineoplastic agent; prodrug |
| thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). | 2.38 | 2 | 0 | aziridines | |
| trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | 3.06 | 1 | 0 | ||
| mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. | 3.75 | 2 | 1 | mitomycin | alkylating agent; antineoplastic agent |
| sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol). | 1.95 | 1 | 0 | glucitol | cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent |
| thymidine [no description available] | 2.36 | 2 | 0 | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite |
| prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. | 5.95 | 8 | 1 | 11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug |
| azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic. | 1.95 | 1 | 0 | N-glycosyl-1,2,4-triazine | antimetabolite; antineoplastic agent; drug metabolite |
| idoxuridine [no description available] | 1.95 | 1 | 0 | organoiodine compound; pyrimidine 2'-deoxyribonucleoside | antiviral drug; DNA synthesis inhibitor |
| diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom. | 1.95 | 1 | 0 | nitrosamine | carcinogenic agent; hepatotoxic agent; mutagen |
| uridine [no description available] | 1.95 | 1 | 0 | uridines | drug metabolite; fundamental metabolite; human metabolite |
| phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group. | 1.95 | 1 | 0 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid | algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| uracil mustard Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | 1.95 | 1 | 0 | aminouracil; nitrogen mustard | |
| mannitol [no description available] | 6.05 | 5 | 1 | mannitol | allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent |
| cytarabine [no description available] | 4.04 | 3 | 1 | beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside | antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent |
| ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5. | 3.06 | 1 | 0 | non-proteinogenic L-alpha-amino acid; ornithine | algal metabolite; hepatoprotective agent; mouse metabolite |
| fluoxymesterone Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women. | 5.93 | 7 | 4 | 11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid | anabolic agent; antineoplastic agent |
| methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone. | 3.35 | 1 | 1 | 6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic |
| ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur. | 1.96 | 1 | 0 | dithiocarbamic acids | chelator; copper chelator |
| quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. | 3.06 | 1 | 0 | azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines | |
| isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent. | 1.96 | 1 | 0 | isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | |
| pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms. | 2.07 | 1 | 0 | diazine; pyrazines | Daphnia magna metabolite |
| azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. | 3.74 | 2 | 1 | N-glycosyl-1,3,5-triazine; nucleoside analogue | antineoplastic agent |
| podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA. | 1.96 | 1 | 0 | furonaphthodioxole; lignan; organic heterotetracyclic compound | antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator |
| galactitol [no description available] | 4.72 | 7 | 1 | hexitol | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite |
| butylhydroxybutylnitrosamine Butylhydroxybutylnitrosamine: A substituted carcinogenic nitrosamine.. N-butyl-N-(4-hydroxybutyl)nitrosamine : A nitrosamine that has butyl and 4-hydroxybutyl substituents. In mice, it causes high-grade, invasive cancers in the urinary bladder, but not in any other tissues. | 1.98 | 1 | 0 | nitrosamine; primary alcohol | carcinogenic agent |
| bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested. | 1.97 | 1 | 0 | diatomic bromine | |
| ancitabine Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action. | 3.34 | 1 | 1 | diol; organic heterotricyclic compound | antimetabolite; antineoplastic agent; prodrug |
| daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola. | 5.69 | 6 | 1 | aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones | antineoplastic agent; bacterial metabolite |
| razoxane Razoxane: An antimitotic agent with immunosuppressive properties. | 4.82 | 4 | 2 | N-alkylpiperazine | |
| fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. | 3.06 | 1 | 0 | nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate | antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug |
| azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3. | 1.98 | 1 | 0 | pseudohalide anion | mitochondrial respiratory-chain inhibitor |
| vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties. | 3.06 | 1 | 0 | ||
| paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | 1.98 | 1 | 0 | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
| etoposide [no description available] | 5.79 | 6 | 4 | beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound | antineoplastic agent; DNA synthesis inhibitor |
| ribavirin Rebetron: Rebetron is tradename | 3.47 | 2 | 0 | 1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide | anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor |
| nimustine Nimustine: Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.. nimustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors. | 3.23 | 1 | 0 | aminopyrimidine; N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent |
| vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). | 1.97 | 1 | 0 | methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid | antineoplastic agent |
| epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | 3.35 | 1 | 1 | aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
| idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. | 1.97 | 1 | 0 | anthracycline antibiotic; deoxy hexoside; monosaccharide derivative | |
| flavone acetic acid flavone acetic acid: structure given in first source | 3.06 | 1 | 0 | ||
| gallium nitrate gallium nitrate: RN given refers to parent cpd | 3.06 | 1 | 0 | ||
| dianhydro-3,4-diacetylgalactitol dianhydro-3,4-diacetylgalactitol: structure given in first source | 1.95 | 1 | 0 | ||
| 3,4,5-trihydroxybenzohydroxamic acid [no description available] | 1.96 | 1 | 0 | ||
| n-hydroxysuccinimide suberic acid ester disuccinimidyl suberate: used as protein cross-linking agent | 1.98 | 1 | 0 | ||
| methotrexate [no description available] | 9.07 | 21 | 7 | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent |
| ritrosulfan ritrosulfan: RN given refers to parent cpd(R*,S*)-isomer; structure | 3.06 | 1 | 0 | ||
| aclacinomycin aklavin: antibiotic prepared from culture liquids of streptomycete (A 1129); possessing antiphage activity; structure. aclacinomycin T : An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage. | 1.98 | 1 | 0 | aminoglycoside; anthracycline; deoxy hexoside; methyl ester; monosaccharide derivative; phenols; polyketide; tertiary alcohol; tetracenequinones; zwitterion | antimicrobial agent; antineoplastic agent; metabolite |
| cilengitide Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | 3.23 | 1 | 0 | oligopeptide | |
| erythritol [no description available] | 3.45 | 2 | 0 | butane-1,2,3,4-tetrol | antioxidant; human metabolite; plant metabolite |
| acivicin [no description available] | 1.96 | 1 | 0 | isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound | antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite |
| bortezomib [no description available] | 2.07 | 1 | 0 | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor |
| dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position. | 1.98 | 1 | 0 | ||
| carboplatin [no description available] | 1.97 | 1 | 0 | ||
| glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2. | 3.05 | 1 | 0 | D-glucosamine | Escherichia coli metabolite; geroprotector; mouse metabolite |
| pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. | 3.06 | 1 | 0 | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
| aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity. | 1.98 | 1 | 0 | aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion | antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
| dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | 2.65 | 3 | 0 | actinomycin | mutagen |
| tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase). | 3.47 | 2 | 0 | 1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide | antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug |
| melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. | 2.39 | 2 | 0 | L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent |
| azidopine azidopine: structure given in first source | 1.98 | 1 | 0 | benzamides | |
| mitobronitol Mitobronitol: Brominated analog of MANNITOL which is an antineoplastic agent appearing to act as an alkylating agent. | 7.05 | 8 | 1 | alcohol; organobromine compound | |
| thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. | 7.04 | 7 | 4 | 2-aminopurines | anticoronaviral agent; antimetabolite; antineoplastic agent |
| tamoxifen [no description available] | 7.44 | 16 | 9 | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator |
| nadp [no description available] | 1.96 | 1 | 0 | ||
| mannomustine Mannomustine: Nitrogen mustard derivative alkylating agent used as antineoplastic. It causes severe bone marrow depression and is a powerful vesicant. | 4.83 | 4 | 0 | amino alcohol | |
| maytansine Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines. | 1.96 | 1 | 0 | alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound | antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator |
| zinostatin Zinostatin: An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic. | 3.34 | 1 | 1 | ||
| mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine. | 3.06 | 1 | 0 | guanidines; hydrazone | antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor |
| gallium Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq. | 3.06 | 1 | 0 | boron group element atom | |
| ribose ribopyranose : The pyranose form of ribose. | 1.96 | 1 | 0 | D-ribose; ribopyranose | |
| jaw [no description available] | 3.1 | 1 | 0 | indolecarboxamide | |
| dianhydrogalactitol Dianhydrogalactitol: One of the cytotoxic dihalohexitols that alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in a disruption of DNA function and cell cycle arrest. It has antineoplastic activity and also causes bone marrow toxicity. | 6.9 | 13 | 1 | ||
| arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding. | 3.76 | 2 | 1 | ||
| carubicin Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group. | 4.26 | 4 | 1 | anthracycline cation | |
| cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). | 3.41 | 1 | 1 | ||
| levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid. | 3.77 | 2 | 1 | 5-formyltetrahydrofolic acid | antineoplastic agent; metabolite |
| guanine [no description available] | 1.96 | 1 | 0 | 2-aminopurines; oxopurine; purine nucleobase | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration. | 11.06 | 9 | 1 | dacarbazine | |
| pyrazofurin pirazofurin : A C-glycosyl compound that is 4-hydroxy-1H-pyrazole-5-carboxamide in which the hydrogen at position 3 has been replaced by a beta-D-ribofuranosyl group. | 1.96 | 1 | 0 | C-glycosyl compound; pyrazoles | antimetabolite; antimicrobial agent; antineoplastic agent; EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Benign Neoplasms, Brain [description not available] | 0 | 10.33 | 24 | 11 |
| Glial Cell Tumors [description not available] | 0 | 8.37 | 9 | 6 |
| Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | 0 | 10.33 | 24 | 11 |
| Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) | 0 | 8.37 | 9 | 6 |
| Carcinoma, Epidermoid [description not available] | 0 | 8.69 | 13 | 6 |
| Cancer of Mouth [description not available] | 0 | 5.76 | 4 | 2 |
| Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) | 0 | 8.69 | 13 | 6 |
| Mouth Neoplasms Tumors or cancer of the MOUTH. | 0 | 5.76 | 4 | 2 |
| Hepatocellular Carcinoma [description not available] | 0 | 2.05 | 1 | 0 |
| Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. | 0 | 2.05 | 1 | 0 |
| Disease Exacerbation [description not available] | 0 | 5 | 3 | 3 |
| Benign Hypothalamic Neoplasms [description not available] | 0 | 3.44 | 1 | 1 |
| Cerebral Primitive Neuroectodermal Tumor [description not available] | 0 | 2.42 | 2 | 0 |
| Cancer of Head [description not available] | 0 | 5.3 | 7 | 2 |
| Cancer of Lung [description not available] | 0 | 5.7 | 11 | 2 |
| Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) | 0 | 5.3 | 7 | 2 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 5.7 | 11 | 2 |
| Neuroectodermal Tumors, Primitive A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059) | 0 | 2.42 | 2 | 0 |
| Anaplastic Astrocytoma [description not available] | 0 | 7.02 | 6 | 2 |
| Astrocytoma, Grade IV [description not available] | 0 | 6.85 | 7 | 4 |
| Benign Supratentorial Neoplasms [description not available] | 0 | 3.39 | 1 | 1 |
| Local Neoplasm Recurrence [description not available] | 0 | 6.98 | 11 | 3 |
| Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082) | 0 | 7.02 | 6 | 2 |
| Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. | 0 | 6.85 | 7 | 4 |
| Acute Myelogenous Leukemia [description not available] | 0 | 6.22 | 7 | 2 |
| Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. | 0 | 6.22 | 7 | 2 |
| Bone Cancer [description not available] | 0 | 4.45 | 5 | 1 |
| Sarcoma, Epithelioid [description not available] | 0 | 4.46 | 5 | 1 |
| Osteogenic Sarcoma [description not available] | 0 | 3.06 | 5 | 0 |
| Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. | 0 | 4.45 | 5 | 1 |
| Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. | 0 | 4.46 | 5 | 1 |
| Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) | 0 | 3.06 | 5 | 0 |
| Blood Diseases [description not available] | 0 | 5.76 | 4 | 2 |
| Hematologic Diseases Disorders of the blood and blood forming tissues. | 0 | 5.76 | 4 | 2 |
| Experimental Hepatoma [description not available] | 0 | 2.36 | 2 | 0 |
| Cancer of Cervix [description not available] | 0 | 6.44 | 6 | 3 |
| Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. | 0 | 6.44 | 6 | 3 |
| Malignant Melanoma [description not available] | 0 | 4.16 | 17 | 0 |
| Metastase [description not available] | 0 | 7.43 | 24 | 6 |
| Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) | 0 | 4.16 | 17 | 0 |
| Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. | 0 | 7.43 | 24 | 6 |
| Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available] | 0 | 6.22 | 7 | 2 |
| Anaplastic Ependymoma [description not available] | 0 | 3.58 | 3 | 0 |
| Ependymoma Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9) | 0 | 3.58 | 3 | 0 |
| Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1) | 0 | 6.22 | 7 | 2 |
| Cancer of Skin [description not available] | 0 | 2.88 | 4 | 0 |
| Skin Neoplasms Tumors or cancer of the SKIN. | 0 | 2.88 | 4 | 0 |
| Adenocarcinoma, Basal Cell [description not available] | 0 | 5.52 | 6 | 3 |
| Cancer of Colon [description not available] | 0 | 2.65 | 3 | 0 |
| Leukocytopenia [description not available] | 0 | 6.69 | 12 | 2 |
| Cancer of Rectum [description not available] | 0 | 2.65 | 3 | 0 |
| Adenocarcinoma A malignant epithelial tumor with a glandular organization. | 0 | 10.52 | 6 | 3 |
| Colonic Neoplasms Tumors or cancer of the COLON. | 0 | 2.65 | 3 | 0 |
| Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). | 0 | 6.69 | 12 | 2 |
| Rectal Neoplasms Tumors or cancer of the RECTUM. | 0 | 2.65 | 3 | 0 |
| Breast Cancer [description not available] | 0 | 9.93 | 35 | 13 |
| Breast Neoplasms Tumors or cancer of the human BREAST. | 0 | 9.93 | 35 | 13 |
| Alopecia Cicatrisata [description not available] | 0 | 3.56 | 3 | 0 |
| Thrombopenia [description not available] | 0 | 5.51 | 9 | 2 |
| Emesis [description not available] | 0 | 3.75 | 2 | 1 |
| Alopecia Absence of hair from areas where it is normally present. | 0 | 3.56 | 3 | 0 |
| Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. | 0 | 3.75 | 2 | 1 |
| Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. | 0 | 4.04 | 3 | 1 |
| Thrombocytopenia A subnormal level of BLOOD PLATELETS. | 0 | 5.51 | 9 | 2 |
| Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. | 0 | 3.75 | 2 | 1 |
| Abnormalities, Autosome [description not available] | 0 | 2.36 | 2 | 0 |
| Di Guglielmo Disease [description not available] | 0 | 1.96 | 1 | 0 |
| Autosomal Chromosome Disorders [description not available] | 0 | 1.96 | 1 | 0 |
| Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. | 0 | 1.96 | 1 | 0 |
| Enlarged Spleen [description not available] | 0 | 2.36 | 2 | 0 |
| Reticulum Cell-Like Sarcoma, Yoshida [description not available] | 0 | 3.34 | 7 | 0 |
| Benign Neoplasms [description not available] | 0 | 7.16 | 12 | 2 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 7.16 | 12 | 2 |
| Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed) | 0 | 1.96 | 1 | 0 |
| Granulocytic Leukemia [description not available] | 0 | 3.06 | 5 | 0 |
| Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. | 0 | 3.06 | 5 | 0 |
| Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) | 0 | 2.65 | 3 | 0 |
| Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. | 0 | 3.34 | 1 | 1 |
| Experimental Neoplasms [description not available] | 0 | 5.76 | 8 | 1 |
| Hemangiopericytoma A tumor composed of spindle cells with a rich vascular network, which apparently arises from pericytes, cells of smooth muscle origin that lie around small vessels. Benign and malignant hemangiopericytomas exist, and the rarity of these lesions has led to considerable confusion in distinguishing between benign and malignant variants. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1364) | 0 | 1.96 | 1 | 0 |
| Cancer of Nasopharynx [description not available] | 0 | 1.96 | 1 | 0 |
| Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. | 0 | 1.96 | 1 | 0 |
| Cancer of Kidney [description not available] | 0 | 2.37 | 2 | 0 |
| Kidney Neoplasms Tumors or cancers of the KIDNEY. | 0 | 2.37 | 2 | 0 |
| Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. | 0 | 2.65 | 3 | 0 |
| Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. | 0 | 1.98 | 1 | 0 |
| Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. | 0 | 3.37 | 1 | 1 |
| Dysmyelopoietic Syndromes [description not available] | 0 | 3.58 | 3 | 0 |
| Cancer, Second Primary [description not available] | 0 | 1.98 | 1 | 0 |
| Acute Disease Disease having a short and relatively severe course. | 0 | 2.88 | 4 | 0 |
| Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. | 0 | 3.58 | 3 | 0 |
| Auricular Cancer [description not available] | 0 | 1.98 | 1 | 0 |
| Choroid Plexus Neoplasms, Primary [description not available] | 0 | 1.98 | 1 | 0 |
| Ear Neoplasms Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR). | 0 | 1.98 | 1 | 0 |
| Choroid Plexus Neoplasms Benign or malignant tumors which arise from the choroid plexus of the ventricles of the brain. Papillomas (see PAPILLOMA, CHOROID PLEXUS) and carcinomas are the most common histologic subtypes, and tend to seed throughout the ventricular and subarachnoid spaces. Clinical features include headaches, ataxia and alterations of consciousness, primarily resulting from associated HYDROCEPHALUS. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2072; J Neurosurg 1998 Mar;88(3):521-8) | 0 | 1.98 | 1 | 0 |
| Carcinoma, Oat Cell [description not available] | 0 | 4.32 | 2 | 2 |
| Carcinoma, Non-Small Cell Lung [description not available] | 0 | 3.38 | 1 | 1 |
| Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. | 0 | 3.38 | 1 | 1 |
| Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) | 0 | 4.32 | 2 | 2 |
| Cutaneous Fistula An abnormal passage or communication leading from an internal organ to the surface of the body. | 0 | 2.92 | 1 | 0 |
| Fistula Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body. | 0 | 2.92 | 1 | 0 |
| Jaw Diseases Diseases involving the JAW. | 0 | 2.92 | 1 | 0 |
| Complication, Postoperative [description not available] | 0 | 3.29 | 2 | 0 |
| Cancer of the Tongue [description not available] | 0 | 2.92 | 1 | 0 |
| Osteoradionecrosis Necrosis of bone following radiation injury. | 0 | 2.92 | 1 | 0 |
| Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. | 0 | 3.29 | 2 | 0 |
| Tongue Neoplasms Tumors or cancer of the TONGUE. | 0 | 2.92 | 1 | 0 |
| Tooth Diseases Diseases involving the TEETH. | 0 | 2.92 | 1 | 0 |
| Cancer of the Uterus [description not available] | 0 | 3.39 | 1 | 1 |
| Uterine Neoplasms Tumors or cancer of the UTERUS. | 0 | 3.39 | 1 | 1 |
| Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. | 0 | 5.5 | 6 | 1 |
| Leukemia L 1210 [description not available] | 0 | 1.95 | 1 | 0 |
| Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw. | 0 | 1.95 | 1 | 0 |
| Bladder Cancer [description not available] | 0 | 7.37 | 2 | 0 |
| Papilloma, Squamous Cell [description not available] | 0 | 2.37 | 2 | 0 |
| Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. | 0 | 2.37 | 2 | 0 |
| Papilloma A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed) | 0 | 2.37 | 2 | 0 |
| Cancer of Pancreas [description not available] | 0 | 1.95 | 1 | 0 |
| Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). | 0 | 1.95 | 1 | 0 |
| Recrudescence [description not available] | 0 | 1.95 | 1 | 0 |
| Bleeding [description not available] | 0 | 1.95 | 1 | 0 |
| Cancer of Larynx [description not available] | 0 | 2.35 | 2 | 0 |
| Laryngeal Diseases Pathological processes involving any part of the LARYNX which coordinates many functions such as voice production, breathing, swallowing, and coughing. | 0 | 1.95 | 1 | 0 |
| Facial Neoplasms New abnormal growth of tissue in the FACE. | 0 | 1.95 | 1 | 0 |
| Hemorrhage Bleeding or escape of blood from a vessel. | 0 | 1.95 | 1 | 0 |
| Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. | 0 | 2.35 | 2 | 0 |
| Germinoblastoma [description not available] | 0 | 2.35 | 2 | 0 |
| Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. | 0 | 2.35 | 2 | 0 |
| Thrombocytopathy [description not available] | 0 | 3.27 | 2 | 0 |
| Blood Platelet Disorders Disorders caused by abnormalities in platelet count or function. | 0 | 3.27 | 2 | 0 |
| Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. | 0 | 2.64 | 3 | 0 |
| EHS Tumor [description not available] | 0 | 1.95 | 1 | 0 |
| Central Nervous System Disease [description not available] | 0 | 1.95 | 1 | 0 |
| Leucocythaemia [description not available] | 0 | 1.95 | 1 | 0 |
| Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. | 0 | 1.95 | 1 | 0 |
| Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) | 0 | 1.95 | 1 | 0 |
| Cancer of Liver [description not available] | 0 | 1.95 | 1 | 0 |
| Neoplasms, Pleural [description not available] | 0 | 1.95 | 1 | 0 |
| Liver Neoplasms Tumors or cancer of the LIVER. | 0 | 1.95 | 1 | 0 |
| Symptom Cluster [description not available] | 0 | 1.95 | 1 | 0 |
| Syndrome A characteristic symptom complex. | 0 | 1.95 | 1 | 0 |
| Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. | 0 | 2.36 | 2 | 0 |
| Granulocytic Leukemia, Chronic [description not available] | 0 | 1.98 | 1 | 0 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. | 0 | 1.98 | 1 | 0 |
| Condition, Preneoplastic [description not available] | 0 | 1.98 | 1 | 0 |
| Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. | 0 | 1.98 | 1 | 0 |
| Precancerous Conditions Pathological conditions that tend eventually to become malignant. | 0 | 1.98 | 1 | 0 |
| B16 Melanoma [description not available] | 0 | 1.98 | 1 | 0 |
| Benign Cerebellar Neoplasms [description not available] | 0 | 1.98 | 1 | 0 |
| Diffuse Mixed Small and Large Cell Lymphoma [description not available] | 0 | 1.96 | 1 | 0 |
| Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. | 0 | 1.96 | 1 | 0 |
| Nervous System Disorders [description not available] | 0 | 3.28 | 2 | 0 |
| Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle. | 0 | 3.28 | 2 | 0 |
| Neutropenia A decrease in the number of NEUTROPHILS found in the blood. | 0 | 1.97 | 1 | 0 |
| Postpartum Amenorrhea [description not available] | 0 | 1.96 | 1 | 0 |
| Dermatitis Medicamentosa [description not available] | 0 | 1.96 | 1 | 0 |
| Amenorrhea Absence of menstruation. | 0 | 1.96 | 1 | 0 |
| Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. | 0 | 1.96 | 1 | 0 |
| Granuloma, Hodgkin [description not available] | 0 | 3.28 | 2 | 0 |
| Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. | 0 | 3.28 | 2 | 0 |
| Acute Liver Injury, Drug-Induced [description not available] | 0 | 1.97 | 1 | 0 |
| Liver Dysfunction [description not available] | 0 | 1.97 | 1 | 0 |
| Porphyria [description not available] | 0 | 1.97 | 1 | 0 |
| Liver Diseases Pathological processes of the LIVER. | 0 | 1.97 | 1 | 0 |
| Porphyrias A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues. | 0 | 1.97 | 1 | 0 |
| Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment. | 0 | 1.97 | 1 | 0 |
| Carcinoma, Anaplastic [description not available] | 0 | 1.96 | 1 | 0 |
| Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer. | 0 | 1.96 | 1 | 0 |
| Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. | 0 | 1.96 | 1 | 0 |
| Cholera Infantum [description not available] | 0 | 1.96 | 1 | 0 |
| Leukemia, Lymphocytic [description not available] | 0 | 2.36 | 2 | 0 |
| Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. | 0 | 2.36 | 2 | 0 |
| Cancer of Testis [description not available] | 0 | 1.95 | 1 | 0 |
| Cancer of the Thyroid [description not available] | 0 | 1.95 | 1 | 0 |
| Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. | 0 | 1.95 | 1 | 0 |
| Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. | 0 | 1.95 | 1 | 0 |
| Mast-Cell Sarcoma A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow. | 0 | 1.95 | 1 | 0 |
| Cancer of the Tonsil [description not available] | 0 | 1.95 | 1 | 0 |
| Respiratory Tract Neoplasms New abnormal growth of tissue in the RESPIRATORY SYSTEM. | 0 | 1.95 | 1 | 0 |
| Tonsillar Neoplasms Tumors or cancer of the PALATINE TONSIL. | 0 | 1.95 | 1 | 0 |
| Agnogenic Myeloid Metaplasia [description not available] | 0 | 1.95 | 1 | 0 |
| Thrombocythemia [description not available] | 0 | 1.95 | 1 | 0 |
| Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. | 0 | 1.95 | 1 | 0 |
| Primary Myelofibrosis A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone. | 0 | 1.95 | 1 | 0 |
| Armstrong Syndrome [description not available] | 0 | 1.94 | 1 | 0 |